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Abstract—The authors tested 123 genotypes described in 54 papers published in the journal Neurology between 1999 and
2002 to ascertain whether these genotype distributions deviated from Hardy–Weinberg equilibrium (HWE). Unreported
deviations from HWE in 19 genotype distributions described in 11 of the papers were discovered. The authors also report
additional information that could have been extracted after calculating HWE and conclude that HWE values should be
mandatory in population genetic studies published in Neurology.
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The gene frequencies at a locus in a randomly inter-
breeding diploid population and population genotype
frequencies remain constant from generation to gen-
eration if mating is random and if mutation, selec-
tion, and migration do not occur. A mathematical
formula created by Hardy and Weinberg1-4 allows for
this equilibrium to be tested in studied populations.
The Hardy–Weinberg law is suitable for testing
the hypothesis of panmixia (random mating within a
breeding population) and evolutionary stasis. It is a
null hypothesis in genetic studies for testing the
suitability of the enrolled reference population and
for detecting even weak associations between geno-
type and disease. However, Hardy–Weinberg equilib-
rium (HWE) is not always calculated and published
in papers investigating population genetics, as we
found after reviewing a sample of papers published
in recent volumes of Neurology.
Subjects and methods. We reanalyzed genotypes described in
papers published in Neurology between 1999 and 2002. Enroll-
ment criteria were investigation of biallelic genetic polymor-
phisms with Mendelian inheritance and case-control study design.
We calculated HWE values for each published genotype in each
subject group using the Arlequin program (http://anthropologie.
unige.ch/arlequin/).6,7 The level of significance was set at p  0.05.
Results. After recalculating distributions of 123 geno-
types described in 54 papers, we found 19 genotypes devi-
ated from HWE (table). In none of the cases did the
authors mention that the HWE p value was under 0.05.
Significant deviation from Hardy–Weinberg expectation
occurred in either control or investigated populations in
three papers, in healthy reference genotypes in four pa-
pers, and in diseased genotypes in five papers.
Discussion. Genotype frequencies may deviate
significantly from the expected values for several
reasons. Deviations should appear in 1 of every 20
genotypes, if the level of significance is set at p 
0.05. However, regardless of the exact mechanism
used to determine deviations, the fact that the distri-
bution of the studied genotype deviates from HWE
should be mentioned by authors. Another frequent,
although often unreported, cause for deviations is
methodologic bias. The applied method might, for
example, not allow for adequate discrimination be-
tween hetero- and homozygotes, potentially leading
to the alteration of genotype distribution. One or
more of the model’s assumptions may also be incor-
rect. Nonrandom mating (inbreeding or an allele ef-
fect on the mating) or gene flow may be occurring,
selection may be operating, or something else evolu-
tionarily interesting could be happening. Deviations
could also be the result of a sampling error. The
sample size could be too small, it might not be from a
single population, or genotypes could have a differ-
ent likelihood of being included in the sample.5 Tak-
ing these possibilities into consideration, authors
should always calculate HW values.
We also found articles in which the populations
being investigated deviated from HWE, but this fact
was unreported. This would appear to discount the
associations, or the lack thereof, put forward in sev-
eral of the papers we sampled in our study. These
include the association between the GSTM3 AA ge-
notype and disability in patients with multiple scle-
rosis and between APOE promoter (219 G/T) and
Alzheimer disease (AD) in Finnish populations as
well as the lack of an association between NOS3
Glu/Asp polymorphism and ischemic stroke, between
sporadic inclusion body myositis and PrP codon 129
methionine homozygosity, between CST3 73 G/A
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polymorphism and AD in Japanese patients, be-
tween dopamine receptor 1.1 or 1.8 and blepharo-
spasm, and between interleukin-1B (511)
polymorphism and AD (see the table).
We found low HWE values in patient populations
in studies investigating ACE D allele in dementia,
Nurr1 gene in subjects with Parkinson disease,
APOE promoter 491 AA genotype in AD in Spanish
subjects, APOE promoter 219 TT genotype in AD
in English and French subjects, -opioid receptor
subunit gene 172 TT genotype in subjects with id-
iopathic generalized epilepsy 2-macroglobulin, and
Val1000 allele in subjects with AD. Although the
authors found significant associations in these stud-
ies, the deviations of genotype distribution in the
patient populations would have been further evi-
dence for the observed associations. This was also
the case when the authors of a paper from the sam-
ple found no association between the cystatin C pro-
moter and increased risk of AD. In spite of the lack
of significant difference between allele or genotype
frequency of control and patient groups, there could
be some association between this genetic variant and
increased risk for the disease, according to the low
HWE value.
These cases suggest that authors should always
calculate HWE and consider the results when evalu-
ating population genetic studies investigating the
significance of a genetic polymorphism of Mendelian
inheritance in human disease.
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Table Papers in Neurology between 1999 and 2002 in which deviations from Hardy–Weinberg equilibrium (HWE) were not noted







p valueAA AB BB AA AB BB
53:418–420 NOS3 gene (Glu/Asp) Control 154 203 36 393 166 179 48 0.0079
54:552–557 GSTM3 Control 221 64 15 300 213 79 8 0.0015
55:1235 Prion protein gene (Met/Val) Controls 156 44 198 398 79 197 122 0.0001
Controls 129 25 146 300 67 149 84 0.0001
Patients 21 1 19 41 11 21 9 0.0001
Patients 14 1 7 22 10 10 2 0.0001
56:1593–1595 ACE I/D Patients 120 239 74 433 132 214 87 0.020
57:337–339 CST3157 G/C Patients 140 33 6 179 137 39 3 0.0387
CST373 G/A Controls 180 40 8 228 175 49 4 0.0091
58:124–126 D1.1 Controls 16 32 42 90 12 41 37 0.0393
D1.8 Controls 17 7 5 29 14 12 3 0.0343
58:881–884 Nurr1 7048G7049 Patients 162 48 15 225 154 64 7 0.0049
58:1566–1568 IL-1B (511) Controls 95 107 15 217 101 94 22 0.0380
59:59–66 APOE promoter (491) Patients 94 18 4 116 91 23 2 0.0312
APOE promoter (219) Controls 67 102 19 188 74 88 26 0.0429
Patients 57 118 100 275 49 134 92 0.0477
Patients 120 361 194 675 134 333 208 0.0444
59:724–728 OPRM1 Patients 193 29 8 230 187 41 2 0.0002
59:756–758 A2M-Ile1000Val Patients 61 48 23 132 55 60 17 0.0244
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